Challenges in the Treatment of Hypertension in Patients With Chronic Kidney Disease
Luis M Ruilope is a professor at Autonomous Uni. of Madrid Dept. of Preventative Medicine Public Health and Microbiology, Spain. Using renin-angiotensin system blockers or mineralocorticoid receptor antagonists in patients with chronic kidney disease may increase potassium levels in the body. He highlights the use of potassium binders to lower potassium levels in CKD patients.
Pathogenesis of Type 2 Diabetes
Viktor Jörgens is a medical doctor and Former Executive Director of the European Association for the Study of Diabetes. He discusses the pathogenesis of different forms of type 2 diabetes, which will help to find individualized diabetes treatment. Scientists looked at data at the time of diagnosis of diabetes and were able to find different clusters with different incidences of complications.
Are ACE Inhibitors Safe in Younger Hypertensive Patients?
Professor Alta Schutte is a leading researcher in hypertension and cardiovascular health. She suggests that Angiotensin-converting enzyme (ACE) inhibitors are very effective in younger hypertensive patients. But this medicine is contraindicated in women planning to become pregnant or may become pregnant as it may cause problems in the unborn child.
What Are the First Line Treatment Options for Hypertension?
Prof. Alta Schutte's research interests focus on identifying early markers for the development of hypertension and prevention of hypertension and cardiovascular disease. She recommends ACE inhibitors, ARBs, and calcium channel blockers as first-line treatment of hypertension. However, beta-blockers can be used in countries or areas with limited resources.
Do Combination Therapies Improve Drug Adherence and Blood Pressure Control in Hypertensive Patients?
Alta Schutte is a professor at the University of New South Wales, Sydney; Professorial Fellow at the George Institute for Global Health; Immediate Past President of the International Society of Hypertension. She suggests that single pill or fixed-dose combination therapy increases long-term adherence to medicines and improves blood control pressure.
Prof. Javed Butler (ESC 2021): EMPEROR Preserved and GUIDE-HF Trials
Prof Javed Butler, chair of the Dept. of Medicine at the Univ. of Mississippi Medical Center, provides some early insights into two clinical trial outcomes in the heart failure world presented at ESC 2021. GUIDE-HF trial looks for CardioMEMS HF System effectiveness in HF patients. EMPEROR Preserved trial looks for Empagliflozin effectiveness in Patients with HFpEF.
Non-Insulin-Producing Human Pancreatic Cells Can Produce Insulin
Pedro L Herrera is a prof. at the Univ. of Geneva Medical School and the director of the university’s Transgenic Core Facility.He provides insight into the plasticity of human pancreatic cells. His recent study has shown that non-insulin-producing human pancreatic cells can be reprogrammed to produce insulin after the loss of beta-cells.
Prof. Emeritus David Matthews (EASD 2019) - CANVAS program and CREDENCE trial
Prof. David Matthews discusses CANVAS and CREDENCE trials focusing on the use of SGLT2 inhibitor Canagliflozin in patients with incipient renal disease. Canagliflozin had significantly improve renal outcomes in the patients. However, amputation risk were different between the two trials. Canagliflozin was linked with increased amputation risk in the CANVAS Program but not in CREDENCE.
Prof. David Matthews (EASD 2019) - Verify Trial
Professor Emeritus David Matthews research focuses on many aspects of type 2 diabetes and he has been involved in many trials, including CANVAS and CANVAS-R and the VERIFY trial. He discusses Verify Trial aiming to determine whether early combination therapy could provide better glycemic control than metformin in patients with newly diagnosed type 2 diabetes.
ESH 2019: New Guidelines on Hypertension
Prof. Massimo Volpe is Professor at Cardiovascular Dept. Univ. of Rome Sapienza, Italy. He is Chief of the Cardiology Division, Dept. of Cardiovascular and Respiratory Science, and Hypertension Unit at Sant’Andrea Hospital, Italy. He discusses hypertension guidelines focusing on the need to control BP in 3 months using combination therapy.
Prof. John McMurray - Contraindications for Empagliflozin
Professor John McMurray's research interests are in heart failure, coronary heart disease, atrial fibrillation and the cardiovascular consequences of diabetes and chronic kidney disease. He advises caution while administering Empagliflozin to patients with type 1 diabetes, history of diabetic ketoacidosis, or genital mycotic infections. However, there is no concern about Kidney function.
EMPEROR Preserved trial - Empagliflozin reduces heart failure hospitalization risk
John McMurray is a professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the Queen Elizabeth University Hospital, Glasgow. He discusses the outcomes of the EMPEROR-Preserved trial which shows that empagliflozin (10 mg once daily) reduces the risk of CV death and Heart Failure hospitalization by 21%.
ADA 2020 - Conference at glance
Key highlights: A study by Dr. Phil Schwabs presented showed minor differences in clinical and cost outcomes between Canagliflozin, Empagliflozin and Dapagliflozin. Yaling Tang presented his finding of ACCORD trial highlighting the benefits of intensive glycemic and BP control in T2D patients. Prof. McMurray presented about effect of Antihyperglycemic medication on heart failure.
Emperor preserved trial - Prof Stefan Anker
Dr. Stefan Anker MD, PhD, FESC, Professor of Homeostasis in Cardiology & Metabolism (2017). Dr. Anker total citations exceed 46,000, including 50 papers with over 200 citations, and he has an h-index of 174. His myriad research interests include the pathophysiology of heart failure, the pathophysiology of cachexia and sarcopenia in chronic heart failure, stroke.
First line of therapy in newly Diagnosed patients by Prof. David Matthews(President EASD 2019)
Emeritus David Matthews is a Professor of Diabetic Medicine, Consultant Physician and Fellow of Harris Manchester College. Prof. Matthews’ research focuses on type 2 diabetes, including mathematical modeling of insulin resistance and the analysis of pulsatile insulin (and other hormones, especially Growth Hormone) using time-series analysis.
Dr DeFronzo with Dr. Akshay Jain - GLP-1 analogs for diabetes management
Dr DeFronzo, a known researcher & endocrinologist, is credited with development of metformin and dapagliflozin. His interests focus on the pathogenesis and treatment of T2DM and Insulin Resistance Syndrome. He summarizes GLP-1 analog benefits: reduces A1C levels, preserves beta-cell function, no risk of hypoglycemia, weight loss, safety profile with cardioprotection.
